SCHEMBL2948017

SCHEMBL2948017

CCc1ccccc1-c1ccc(CN)c(F)c1

nearest known ligand 0.54

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALOX5AP P20292 9/20 0.54
FEN1 P39748 9/20 0.54
DPP4 P27487 1/20 0.46
TRPA1 O75762 1/20 0.44
CSNK2A2 P19784 1/20 0.44
CSNK2B P67870 1/20 0.44
CSNK2A1 P68400 1/20 0.44
CSNK2A3 Q8NEV1 1/20 0.44
FFAR1 O14842 1/20 0.43
FFAR4 Q5NUL3 1/20 0.43
PDE3B Q13370 1/20 0.41
PDE3A Q14432 1/20 0.41
LTB4R2 Q9NPC1 1/20 0.41
NOS3 P29474 1/20 0.41
NOS1 P29475 1/20 0.41
NOS2 P35228 1/20 0.41
BDKRB1 P46663 2/20 0.40
F10 P00742 1/20 0.40
LOX P28300 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2949321 0.89 ALOX5AP (0.53) ALOX5APFEN1TRPA1CSNK2A2CSNK2B
SCHEMBL23347204 0.83 ALOX5AP (0.56) ALOX5APFEN1TRPA1FFAR1FFAR4
SCHEMBL5992838 0.83 PTPRC (0.47) ALOX5APFEN1DPP4TRPA1BDKRB1
SCHEMBL21725425 0.82 HTR7 (0.51) ALOX5APFEN1DPP4TRPA1FFAR1
SCHEMBL3756934 0.80 DPP4 (0.57) ALOX5APFEN1DPP4NOS3NOS1
SCHEMBL21725424 0.78 ALOX5AP (0.53) ALOX5APFEN1DPP4TRPA1FFAR1
SCHEMBL28743346 0.78 XDH (0.38) ALOX5APFEN1DPP4NOS3NOS1
SCHEMBL9287992 0.78 ALOX5AP (0.50) ALOX5APFEN1TRPA1CSNK2A2CSNK2B
SCHEMBL2949319 0.77 ALOX5AP (0.54) ALOX5APFEN1TRPA1PDE3BPDE3A
SCHEMBL7265195 0.77 ALOX5AP (0.56) ALOX5APFEN1F10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11566015-B2 Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof Crinetics Pharmaceuticals, Inc. (US) 2023-01-31 US disclosed
US-20210238164-A1 MELANOCORTIN SUBTYPE-2 RECEPTOR (MC2R) ANTAGONISTS AND USES THEREOF Crinetics Pharmaceuticals, Inc. 2021-08-05 US disclosed
US-10604507-B2 Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof Crinetics Pharmaceuticals, Inc. (US) 2020-03-31 US disclosed
EP-2396301-A2 SMALL MOLECULE BRADYKININ B1 RECEPTOR ANTAGONISTS Jerini AG (DE) 2011-12-21 EP disclosed
WO-2010091876-A2 SMALL MOLECULE BRADYKININ B1 RECEPTOR ANTAGONISTS JERINI AG (DE) 2010-08-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11566015-B2 Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof MC3R, MC1R, MC2R ALOX5AP 1073/4885FEN1 4826/4885DPP4 898/4885
US-20210238164-A1 MELANOCORTIN SUBTYPE-2 RECEPTOR (MC2R) ANTAGONISTS AND USES THEREOF MC3R, MC1R, MC2R ALOX5AP 1073/4885FEN1 4826/4885DPP4 898/4885
US-10604507-B2 Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof MC3R, MC1R, MC2R ALOX5AP 1073/4885FEN1 4826/4885DPP4 898/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.